|
|
Article: Rhone-Poulenc Rorer Receives Approval for DDAVP(R) Tablets for Treatment Of Primary Nocturnal Enuresis
- Article from:
- PR Newswire
- Article date:
- March 27, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tablets Offer Convenience to Families With Children Who Wet the Bed
COLLEGEVILLE, Pa., March 27 /PRNewswire/ -- Rhone-Poulenc Rorer, a global pharmaceutical subsidiary of Rhone-Poulenc S.A. (NYSE: RP), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the tablet formulation of DDAVP (desmopressin acetate) for the management of primary nocturnal enuresis (PNE), commonly known as bed-wetting, in patients aged 6 and over.
DDAVP has been available in a nasal spray form for bed-wetting since its introduction in 1989.
DDAVP is a synthetic form of vasopressin, an antidiuretic hormone ...